Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone732-537-6200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.46 billion
Profitability
Miscellaneous
Employees10,700
Next Earnings Date8/27/2019 (Estimated)
OptionableOptionable
Catalent (NYSE:CTLT) Frequently Asked Questions
What is Catalent's stock symbol?
Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."
How were Catalent's earnings last quarter?
Catalent Inc (NYSE:CTLT) released its quarterly earnings results on Tuesday, May, 7th. The company reported $0.49 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.42 by $0.07. The business earned $617.50 million during the quarter, compared to analysts' expectations of $644.88 million. Catalent had a return on equity of 16.78% and a net margin of 6.01%. The firm's revenue for the quarter was down 1.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.41 earnings per share. View Catalent's Earnings History.
When is Catalent's next earnings date?
What guidance has Catalent issued on next quarter's earnings?
Catalent issued an update on its FY 2019 earnings guidance on Tuesday, May, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.5-2.52 billion, compared to the consensus revenue estimate of $2.54 billion.
What price target have analysts set for CTLT?
7 analysts have issued twelve-month price objectives for Catalent's shares. Their predictions range from $45.00 to $62.00. On average, they expect Catalent's share price to reach $52.50 in the next year. This suggests that the stock has a possible downside of 0.4%. View Analyst Price Targets for Catalent.
What is the consensus analysts' recommendation for Catalent?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalent.
Has Catalent been receiving favorable news coverage?
News stories about CTLT stock have trended somewhat positive on Tuesday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Catalent earned a daily sentiment score of 1.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an impact on the stock's share price in the near future. View News Stories for Catalent.
Who are some of Catalent's key competitors?
Some companies that are related to Catalent include Alexion Pharmaceuticals (ALXN), Takeda Pharmaceutical (TAK), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Array Biopharma (ARRY), Sarepta Therapeutics (SRPT), SAGE Therapeutics (SAGE), Mylan (MYL), Ionis Pharmaceuticals (IONS), Ono Pharmaceutical (OPHLF), Teva Pharmaceutical Industries (TEVA) and Bausch Health Companies (BHC).
What other stocks do shareholders of Catalent own?
Who are Catalent's key executives?
Catalent's management team includes the folowing people:
- Mr. John R. Chiminski, Chairman & CEO (Age 55)
- Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 47)
- Mr. Steven L. Fasman, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
- Mr. Jonathan Arnold, Pres of Oral Drug Delivery Bus. Unit (Age 53)
- Mr. Alessandro Maselli, Pres & COO (Age 47)
Who are Catalent's major shareholders?
Catalent's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (12.02%), BlackRock Inc. (9.56%), William Blair Investment Management LLC (2.80%), Champlain Investment Partners LLC (2.69%), FMR LLC (2.38%) and Jennison Associates LLC (0.79%). Company insiders that own Catalent stock include Aristippos Gennadios, Barry Littlejohns, Christine Dolan, Donald E Morel, Jr, Gregory T Lucier, John J Greisch, John R Chiminski, Lance Miyamoto, Peter L Buzy, Steven L Fasman, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent.
Which institutional investors are selling Catalent stock?
CTLT stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Marshall Wace LLP, FMR LLC, Martingale Asset Management L P, Globeflex Capital L P, ETF Managers Group LLC, Emerald Advisers LLC and AlphaCrest Capital Management LLC. Company insiders that have sold Catalent company stock in the last year include Aristippos Gennadios, Barry Littlejohns, John R Chiminski, Lance Miyamoto and William Downie. View Insider Buying and Selling for Catalent.
Which institutional investors are buying Catalent stock?
CTLT stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, BlackRock Inc., Lazard Asset Management LLC, Bank of Montreal Can, Eagle Asset Management Inc., Westfield Capital Management Co. LP, SG Americas Securities LLC and Champlain Investment Partners LLC. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, Gregory T Lucier, John J Greisch, Peter L Buzy and Uwe Roehrhoff. View Insider Buying and Selling for Catalent.
How do I buy shares of Catalent?
Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Catalent's stock price today?
One share of CTLT stock can currently be purchased for approximately $52.70.
How big of a company is Catalent?
Catalent has a market capitalization of $7.68 billion and generates $2.46 billion in revenue each year. The company earns $83.60 million in net income (profit) each year or $1.59 on an earnings per share basis. Catalent employs 10,700 workers across the globe.View Additional Information About Catalent.
What is Catalent's official website?
How can I contact Catalent?
Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]
MarketBeat Community Rating for Catalent (NYSE CTLT)
MarketBeat's community ratings are surveys of what our community members think about Catalent and other stocks. Vote "Outperform" if you believe CTLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
